Caris Life Sciences (CAI) Registration Filing summary

Company overview and business model

• Develops and commercializes AI-driven precision medicine solutions, focusing on comprehensive molecular profiling for oncology and other chronic diseases.

• Operates both tissue-based (MI Profile) and blood-based (Caris Assure) molecular profiling platforms, leveraging large-scale clinico-genomic datasets.

• Partners with biopharma for R&D, data licensing, and drug discovery, and maintains a global network of academic collaborators.

• Holds a significant proprietary dataset from over 6.5 million tests, enabling AI/ML-driven innovation and new product development.

Financial performance and metrics

• 2024 revenue: $412.3 million (up 34.7% from 2023); Q1 2025 revenue: $120.9 million (up 49.9% YoY).

• Net loss: $281.9 million in 2024 (improved from $341.4 million in 2023); Q1 2025 net loss: $102.6 million.

• Adjusted EBITDA: $(189.6) million in 2024; $(36.2) million in Q1 2025.

• Negative cash flow from operations: $245.2 million in 2024; cash and equivalents of $33.4 million as of March 31, 2025.

• $400 million in outstanding term loan debt as of March 31, 2025.

Use of proceeds and capital allocation

• IPO proceeds intended for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• A portion will be used to satisfy anticipated tax withholding and remittance obligations related to RSU settlements.

• Management has broad discretion over use of funds; may also pursue acquisitions or investments.